Ketotifen
|  | |
| Systematic (IUPAC) name | |
|---|---|
| 4-(1-Methylpiperidin-4-ylidene)-4,9-dihydro-10H-benzo[4,5]cyclohepta[1,2-b]thiophen-10-one | |
| Clinical data | |
| Trade names | Zaditor[1] | 
| AHFS/Drugs.com | Micromedex Detailed Consumer Information | 
| MedlinePlus | a604033 | 
| Pregnancy category | 
 | 
| Legal status | 
 | 
| Routes of administration | Oral (tablets), ophthalmic solution | 
| Pharmacokinetic data | |
| Bioavailability | 60% | 
| Protein binding | 75% | 
| Metabolism | Hepatic | 
| Biological half-life | 12 hours | 
| Identifiers | |
| CAS Number | 34580-14-8  | 
| ATC code | R06AX17 S01GX08 | 
| PubChem | CID 3827 | 
| IUPHAR/BPS | 7206 | 
| DrugBank | DB00920  | 
| ChemSpider | 3695  | 
| UNII | HBD503WORO  | 
| KEGG | D01332  | 
| ChEMBL | CHEMBL534  | 
| Chemical data | |
| Formula | C19H19NOS | 
| Molar mass | 309.426 g/mol | 
| 
 | |
| 
 | |
| (verify) | |
Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis,[2] or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
Uses
Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after administering the drops. The drug has not been studied in children under three.[2] The mean elimination half life is 12 hours.[3] Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor.
The drug may also help relieve the symptoms of irritable bowel syndrome.[4]
Side effects
Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds.
Brands
Ketotifen is marketed under many brand names worldwide.[5]
See also
References
- ↑ http://www.webmd.com/drugs/2/drug-17484/zaditor-opht/details
- 1 2 Zaditor prescribing information Novartis
- ↑ Grahnén A; Lönnebo A; Beck O; Eckernäs SA; Dahlström B; Lindström B (May 1992). "Pharmacokinetics of ketotifen after oral administration to healthy male subjects". Biopharm Drug Dispos 13 (4): 255–262. doi:10.1002/bdd.2510130404. PMID 1600111.
- ↑ Klooker, TK; Braak, B; Koopman, KE; Welting, O; Wouters, MM; Van Der Heide, S; Schemann, M; Bischoff, SC; et al. (2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome". Gut 59 (9): 1213–21. doi:10.1136/gut.2010.213108. PMID 20650926.
- ↑ drugs.com International availability of ketofin Page accessed April 21, 2015
External links
| 
 | ||||||||||||||||||||||||||||||
| 
 | ||||||||||||||||||||||||||